Grant-in-Aid for Scientific Research (A).
|Research Institution||TOHOKU UNIVERSITY|
FUJIMURA Shigefumi Institute of Development, Aging and Cancer, Tohoku University. Professor, 加齢医学研究所, 教授 (40006078)
SHIRATO Kunio First Department of Internal Medicine, Tohoku University. Professor, 医学部, 教授 (80004761)
KOYANAGI Hitosi Department of Cardiovascular Surgery, Tokyo Women's Medical Colledge. Professor, 教授 (90138884)
MATSUDA Hikaru First Department of Surgery, Osaka University. Professor, 医学部, 教授 (00028614)
人見 滋樹 京都大学, 胸部疾患研究所, 教授 (80173186)
KATO Harufumi Department of Surgery, Tokyo Medical College. Professor, 教授 (20074768)
AYABE Hiroyosi First Department of Surgery, Nagasaki University. Professor, 医学部, 教授 (60128147)
|Project Fiscal Year
1997 – 1999
Completed(Fiscal Year 1999)
|Budget Amount *help
¥26,600,000 (Direct Cost : ¥26,600,000)
Fiscal Year 1999 : ¥8,100,000 (Direct Cost : ¥8,100,000)
Fiscal Year 1998 : ¥6,500,000 (Direct Cost : ¥6,500,000)
Fiscal Year 1997 : ¥12,000,000 (Direct Cost : ¥12,000,000)
|Keywords||Lung Transplantation / Heart-Lung Transplantation / Pulmonary Preservation / Immunosuppression / Reection Monitoring / Non-Heart-Beatig Donor / 肺保存 / 肺胞水分クリアランス / 肺水腫 / 肺胞上皮機能 / 副腎皮質ホルモン / 肺移植 / 心肺移植 / 適応拡大 / 肺・心肺保存 / 移植後肺水腫 / 心停止ドナー|
(1) Clinical indication
<Chronic pulmonary emphysema> Incidence of the juvenile type emphysema for lung transplantation in our country was found to be 1 to 2% of all, and the benefit of volume reduction surgery as a bridge therapy has been established.
<Primary pulmonary hypertension> Effectiveness of the prostacyclin treatment has been established to date, however, some patients were found to be resistant to this treatment.
<Others> Potential candidates for lung transplantation were most frequently found in patients with idiopathic pulmonary fibrosis among several disease entity (idiopathic pulmonary fibrosis, pulmonary lymphoangiomyomatosis, bronchilitis obliterans, pulmonary emphysema).
(2) Basic research
1) Expansion of the donor pool
Possibility of lung transplantation from non-heart-beating donor was demonstrated, and the research on the size matching in living-related lobar transplantation has been started.
Fetal lung as a low antigen-presenting model was challenged for zenograft and its usefulness was suggested. Researches on the mechanisms of immune reaction in zenotransplantation has been progressed.
3) Posttransplant patient management
Platelet was found to be contributory in reimplantation response. Triptolide, a kind of Chinese medicine, was found to be a potent immunosuppressive agent. Molecular biological technique (gene transfection) has been strated to be applied for immunosuppression in both acute and chronic rejection in lung transplantation.